Please login to the form below

Not currently logged in
Email:
Password:

Hugh Cole leaves Shire for Ariad

Appointed chief business officer at company behind Iclusig

Ariad, Hugh ColeHugh Cole has left his role at Shire to join Ariad Pharmaceuticals as chief business officer.

In this role Cole will report to CEO Dr Harvey Berger and will be responsible for the company's global business and corporate development, licensing and strategic planning.

Cole spent seven years at Shire, most recently as senior VP, strategic planning and programme management. Prior to this he was a global franchise lead and VP, business development.

At Shire he gained experience in the orphan drugs market, which will benefit Ariad as it prepares to grow its portfolio of drugs targeted to treat rare, difficult-to-treat forms of cancer.

This includes its only current marketed product Iclusig, which is recommended to treat chronic myeloid leukaemia and T315I-positive Philadelphia chromosome positive acute lymphoblastic leukaemia.

The appointment of a chief business officer is a sign of confidence from Ariad, which last year faced safety concerns about Iclusig, but has since seen the drug backed by both the EMA and the FDA, although with new safety recommendations.

CEO Berger said: “[Cole] will be integral in seeking business and corporate development opportunities for Ariad, including a commercial partnership for Iclusig in Japan, as well as helping to further maximise our oncology pipeline.”

8th April 2014

From: Sales

Share

Tags

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Page & Page and Partners

For those who can imagine better, Page & Page and Partners (P&P) is home to meaningful encounters of a marketing, communication...

Latest intelligence

Why big pharma needs to be braver
The last few years have seen the pharmaceutical industry undergo a rapid metamorphosis in the face of unprecedented change, but communications are one area that still needs an injection of...
Leveraging Real-World Evidence for Cell and Gene Therapies
Regulators and reimbursement bodies are increasingly turning to real-world evidence (RWE) to understand the long-term value of drugs, in particular novel therapies. Here, Mariam Bibi, Senior Director, Global RWE at...
Food Allergy – Is avoidance the only option?
Following on from Allergy Awareness Week 2022, we’re continuing the discussion about food allergies and the experiences of those who live with them. In this blog, we discuss the current...